Beijing Science Sun Pharmaceutical Co.,LTD.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Beijing Saisheng Pharmaceutical Co., Ltd. was established in May 1999 and renamed Beijing Saisheng Pharmaceutical Co., Ltd. in July 2011. It was listed on the Shenzhen Stock Exchange in June 2015 (SZ: 300485) and is a national high-tech biopharmaceutical enterprise covering high-end formulations, biopharmaceuticals, modern Chinese medicine, raw materials, health products, medical devices, and other fields. Saisheng Pharmaceutical is rooted in the pharmaceutical industry, with innovation and research and development as the foundation, market and sales oriented, safety and effectiveness as the guarantee, and service as the purpose. It is committed to the industrialization development of life science technology, accelerating the layout of related fields covering life science and big health industries through independent innovation, integration of upstream and downstream industry chains, and capital market operation, effectively achieving industrial strategic expansion plans and capital appreciation. Over the past 20 years, the company has successfully developed 29 varieties and 61 specifications of listed drugs, obtained 3 new drug certificates, and has undertaken scientific and technological innovation work such as the 863 special project, national major new drug development, independent innovation products, Torch Plan, and national key new products. It has authorized 45 patents, and currently has more than 20 research projects, including 2 Class I chemical drugs, 1 Class III chemical drug, and 2 Class II biological similar drugs, which have entered the clinical trial stage. The company has engaged in long-term and in-depth cooperation with domestic and foreign universities and research institutions to achieve industrial transformation of multiple research projects. The company currently has two production bases, both located in Beijing Yizhuang Economic and Technological Development Zone. It has three subsidiaries: Beijing Saier Biopharmaceutical Co., Ltd., Shenyang Junyuan Pharmaceutical Co., Ltd., and Saisheng Pharmaceutical Hong Kong Co., Ltd. It participates in Beijing Huada Protein Research and Development Center Co., Ltd., Beijing Green Bamboo Biotechnology Co., Ltd., Zhejiang Sailing Pharmaceutical Technology Co., Ltd., and participates in the establishment of the first phase of the biopharmaceutical merger and acquisition fund and the second phase of the biopharmaceutical merger and acquisition fund Suzhou Danqing Phase II Innovative Pharmaceutical Industry Investment Partnership Enterprise, Beijing Hetang Life Science Original Innovation Fund, and Pharmaceutical Small and Medium sized Enterprise Fund, among others, deeply cultivate the pharmaceutical field, integrate and accumulate, and make unremitting efforts to achieve the vision of building a well-known large health enterprise group with core competitiveness. |
| Headquarter | Beijing |
| Establish Date | 5/20/1999 |
| Listed Code | 300485.SZ |
| Listed Date | 6/26/2015 |
| Chairman | Ma Yan. |
| CEO | Ma Yan. |
| Website | www.ssyy.com.cn |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
